Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe

References

• KatzPOGersonLBVelaMFGuidelines for the diagnosis and management of gastroesophageal reflux diseaseAm J Gastroenterol2013108330832823419381
   PubMed Web of Science ®Google Scholar
• DentJEl-SeragHBWallanderMAJohanssonSEpidemiology of gastro-oesophageal reflux disease: a systematic reviewGut200554571071715831922
   PubMed Web of Science ®Google Scholar
• ShinJMSachsGPharmacology of proton pump inhibitorsCurr Gastroenterol Rep200810652853419006606
   PubMedGoogle Scholar
• HowdenCWReview article: immediate-release proton-pump inhibitor therapy – potential advantagesAliment Pharmacol Ther200522Suppl 3253016303034
   PubMed Web of Science ®Google Scholar
• EmersonCRMarzellaNDexlansoprazole: a proton pump inhibitor with a dual delayed-release systemClin Ther20103291578159620974316
   PubMed Web of Science ®Google Scholar
• MetzDCVakilyMDixitTMulfordDReview article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapyAliment Pharmacol Ther200929992893719298580
   PubMed Web of Science ®Google Scholar
• Dexilant® (dexlansoprazole) delayed-release capsules [package insert]Deerfield, ILTakeda Pharmaceuticals America, Inc2016 Available from: http://general.takedapharm.com/content/file.aspx?filetypecode=DEXILANTPI&cacheRandomizer=b1b7fc2b-e156-45b4-aa38-98b0bc2d4ec1Accessed April 6, 2017
   Google Scholar
• VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trialsCurr Med Res Opin200925362763819232037
   PubMed Web of Science ®Google Scholar
• LeeRDVakilyMMulfordDWuJAtkinsonSNClinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibilityAliment Pharmacol Ther200929882483319243357
   PubMed Web of Science ®Google Scholar
• KukulkaMEisenbergCNudurupatiSComparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgClin Exp Gastroenterol20114421322022016582
   PubMedGoogle Scholar
• FassRJohnsonDAOrrWCThe effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERDAm J Gastroenterol2011106342143121224838
   PubMed Web of Science ®Google Scholar
• HowdenCWLarsenLMPerezMCPalmerRAtkinsonSNClinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom reliefAliment Pharmacol Ther200930989590719681809
   PubMed Web of Science ®Google Scholar
• PeuraDAMetzDCDabholkarAHParisMMYuPAtkinsonSNSafety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experienceAliment Pharmacol Ther200930101010102119735233
   PubMed Web of Science ®Google Scholar
• WittbrodtETBaumCPeuraDADelayed release dexlansoprazole in the treatment of GERD and erosive esophagitisClin Exp Gastroenterol2009211712821694835
   PubMedGoogle Scholar
• LiuFRanmalSBatchelorHKPatient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populationsDrugs201474161871188925274536
   PubMed Web of Science ®Google Scholar
• ChoSYChoungRSSaitoYAPrevalence and risk factors for dysphagia: a USA community studyNeurogastroenterol Motil201527221221925376877
   PubMed Web of Science ®Google Scholar
• LockeGR3rdTalleyNJFettSLZinsmeisterARMeltonLJ3rdPrevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, MinnesotaGastroenterology19971125144814569136821
   PubMed Web of Science ®Google Scholar
• VakilNBTraxlerBLevineDDysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatmentClin Gastroenterol Hepatol20042866566815290658
   PubMed Web of Science ®Google Scholar
• DanielsSKNeurological disorders affecting oral, pharyngeal swallowingGI Motil Online2006 Available from: https://www.nature.com/gimo/contents/pt1/full/gimo34.htmlAccessed August 29, 2018
   Google Scholar
• JaradehSMuscle disorders affecting oral and pharyngeal swallowingGI Motil Online2006 Available from: https://www.nature.com/gimo/contents/pt1/full/gimo35.htmlAccessed August 29, 2018
   Google Scholar
• SheehanNJDysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseasesRheumatology (Oxford)200847674675218326539
   PubMed Web of Science ®Google Scholar
• SoniesBCDalakasMCDysphagia in patients with the post-polio syndromeN Engl J Med199132417116211672011159
   PubMed Web of Science ®Google Scholar
• YanBMShafferEAEosinophilic esophagitis: a newly established cause of dysphagiaWorld J Gastroenterol200612152328233416688820
   PubMed Web of Science ®Google Scholar
• CioconJOIndications for tube feedings in elderly patientsDysphagia199051152118023
   PubMedGoogle Scholar
• StroudMDuncanHNightingaleJBritish Society of GastroenterologyGuidelines for enteral feeding in adult hospital patientsGut200352(Suppl 7vii1vii1214612488
   PubMedGoogle Scholar
• CzerniakRVakilyMWuJTAK-390MR, a Novel Dual Delayed Release Formulation of a PPI, is Bioequivalent When Administered as Granules Sprinkled Over Applesauce or as an Intact CapsulePaper presented at: 73rd Annual Scientific Meeting of the American College of GastroenterologyOctober 3–8; 2008Orlando, FL
   Google Scholar
• KukulkaMNudurupatiSPerezMCPharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux diseaseClin Exp Gastroenterol2014746147125525378
   PubMedGoogle Scholar
• AslamNWrightRDexlansoprazole MRExpert Opin Pharmacother200910142329233619708852
   PubMed Web of Science ®Google Scholar
• GrabowskiBLeeRDAbsorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjectsClin Drug Investig2012325319332
   Web of Science ®Google Scholar
• Food and Drug AdministrationGuidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs – general considerationsBethesda, MDCenter for Drug Evaluation and Research (CDER), Food and Drug Administration2014 Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdfAccessed August 29, 2018
   Google Scholar
• Food and Drug AdministrationGuidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerationsWashington, DCFood and Drug Administration2003 Available from: https://www.ipqpubs.com/wp-content/uploads/2014/04/BABEOld.pdfAccessed August 29, 2018
   Google Scholar
• FDAAA 801 RequirementsClinicaltrials.gov Web site Available from: https://clinicaltrials.gov/ct2/manage-recs/fdaaaAccessed April 6, 2016
   Google Scholar
• GrissingerMOral syringes: making better use of a crucial and economical risk-reduction strategyP T20133815623599662
   PubMedGoogle Scholar